Piperazine → 4-Piperazin-1-yl-1-tritylbenzimidazole

HRID 746

反応式

HRID 746 の反応式
Brc1cccc2c1ncn2C(c1ccccc1)(c1ccccc1)c1ccccc1.C1CNCCN1>CC(C)(C)[O-].Cc1ccccc1.ClC(Cl)Cl.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.[Na+].[Pd].[Pd].c1ccc(P(c2ccccc2)c2ccc3ccccc3c2-c2c(P(c3ccccc3)c3ccccc3)ccc3ccccc23)cc1>c1ccc(C(c2ccccc2)(c2ccccc2)n2cnc3c(N4CCNCC4)cccc32)cc1

参加物

7

反応条件

温度
90 °C

実験手順

A 2.0-5.0 mL microwave vial was charged with 4-bromo-1-trityl-1H-benzo[d]imidazole (300 mg, 0.68 mmol), Sodium tert- butoxide (92 mg, 0.96 mmol), rac-2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl (25.5 mg, 0.04 mmol), Piperazine (0.321 mL, 4.10 mmol) and toluene (5 mL). The reaction mixture was degassed for 10 minutes with nitrogen, and then Tris(dibenzylideneacetone)dipalladium(0)-chloroform adduct (14.14 mg, 0.01 mmol) was added. The reaction mixture was stirred at 90°C under microwave irradiation for 1h. The solution was diluted with EtOAc and washed with water, saturated NaHCO3 solution, brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced vacuum. The crude material was loaded on a 24g silica gel column and purified on a Teledyne Isco instrument, eluting with 10 : 1 / DCM : MeOH containing 0.2% ammonium hydroxide (v/v) to provide 4-(piperazin-1-yl)-1-trityl-1H-benzo[d]imidazole (130 mg, 42.8 %) as a solid. The product was analyzed by analytical HPLC MS using the high pH gradient method (mobile phase: 5-95% B; A: H2O with 10 mM NH5CO3 and 0.375% NH4OH v/v, B: MeOH, 2.25 min run) on X-Bridge C18, 2.1 x 30 mm, 5 mm particle size. MS _m/z_ 445.6 [M+H]\+ (ESI), Rt 2.61 min; 1H NMR (400 MHz, CHLOROFORM-d) d ppm 1.64 (br. s., 1 H), 3.11 - 3.22 (m, 4 H), 3.48 - 3.59 (m, 4 H), 6.08 (d, J=8.20 Hz, 1 H), 6.54 (d, J=7.42 Hz, 1 H), 6.79 (t, J=8.01 Hz, 1 H), 7.13 - 7.23 (m, 6 H), 7.30 (d, J=3.91 Hz, 9 H), 7.79 (s, 1 H).

出典と根拠

ORDレコード
ord-2d4ae739f81c45c1ab0faf1d764941ef
出典データセット
750 AstraZeneca ELN dataset
元リンク
出典を表示

関連ノート

読み込み中…